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The studies described in this thesis were performed in patients with asthma. Asthma is
characterised by episodes of dyspnea and/or wheezing and variable airway obstruction.
Histopathologically, asthma is characterised by a chronic inflammation of the airways. The
mainstream of asthma treatment consists of anti-inflammatory therapy and the use of
inhaled corlicosteroids is therefore advised in all asthma guidelines ". This thesis aims at
establishing the rationale for dosing strategies of inhaled corticosteroids in asthmatics using
traditional and new techniques. The results of this thesis are summarised below.
ASTHMA GUIDELINES AND SELF.MANAGEMENT PLANS
When physicians became more aware of the inflammatory pathophysiology of asthma,
several asthma guidelines were developed. These guidelines included classification,
medication plans, self-management plans, and management of exacerbations and were not
unifbrm in their recommendations. In Chapter 2 a comparison of 5 intemational asthma
guidelines was made. Guidelines differed for instance regarding the levels of severity of
asthma at which ICS should be started. Additionally, the rules for stepping down the use of
ICS received little attention, were imprecise, and had hardly been backed-up by adequate
studies. One example of the latter is the GINA guideline that states: "if control is sustained
fbr at least three months, a gradual stepwise reduction in treatment may be possible" r;
neither the definition of control nor the algorithm for dose reduction is provided. Treatment
changes in self-management plans are generally guided by change in peak expiratory flow
(PEF) and symptoms. We do not think that these parameters, especially PEF, are attractive
for all patients in making a decision when and how to change the dosage of inhaled
corticosteroids because monitoring by daily PEF measurements is not very practical in
daily use (time consuming. stigmatisation, size of apparatus as camy-on luggage, Chapter
2). Additionally changes in ICS doses in self-management plans are dictated much more
frequently by symptoms than by PEF changes (Chapter I l).
START THERAPY: ORAL OR INHALED CORTICOSTEROIDS
Most diagnosed patients with asthma have to start with anti-inflammatory therapy and
patients who are not optimally treated have to augment this treatment. Several asthma
guidelines state that fast suppression of inflammation and reduction in symptoms should be
aimed for ''*. It has been stated that a course of oral prednisolone (30-40 mg/day) is the best
therapy in this situation'. We investigated in Chapter J whether inhaled fluticasone could
serve as an altemative treatment to oral cofticosteroids in case of poorly controlled asthma.
We expected a similar or slightly worse clinical response to fluticasone, but with a
favourable side-effect profile. However, we found inhaled fluticasone in a dose of 2000
prg/day to be superior to oral prednisolone for two weeks (30 mgiday). This was specifically
true when improvement of asthma control was assessed by tests of bronchial
hyperresponsiveness (methacholine and adenosine-5'-monophosphate). A significant
decrease of blood eosinophils and ECP was fbund with inhaled fluticasone 2000 pglday
compared to 500 'p"glday. The clinical efl'ects of a lower dose (500 pg/day) were
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surrogate marker of systernic suppression by corticosteroids, appeared in our first analysis
to be equally suppressed by oral prednisolone (30 mg/day) and fluticasone 2000 pg/day.
This measurement of corlisol was perforrned by conventional RIA method and it was
pointed out to us that cross-reaction with oral prednisolone occurs in analyses ofcortisol by
RtA 5. Re-analysis with an HPLC method sholved that cortisol levels in serllm \\/ere lower
in the oral prednisolone group compared to the fluticasone 2000 prg/day group, which in
turn was lor.ver than in the fluticasone 500 pglday group. Thus, systemic side effects, as
measured with serurn cortisol are less with high doses of inhaled fluticasone than with oral
prednisolone, but are still clearly measurable.
PREDICTING CLINICAL BENEFIT FROM CORTICOSTEROIDS
hr general, corlicosteroids improve asthma symptonrs yet this is not the case fbr all patients
to the same extent. Horv well an irrdividual patient with newly diagnosed asthma or with
insufficient asthma control will respond to therapy is a cornmon and clinically irnporlant
question. ln Chapter 4 we set out to detennine whether we could predict a f-avourable short-
term clinical response to corticosteroids in patients rvith asthma. We fbund that steroid
induced changes in FEVI, PC36 Mch, and QOL were predominantly predicted by their
respective baseline value and to a smaller extent by eosinophils in blood or sputum. The
value of ECP levels measured in blood or sputum for predicting the response to
cofticosteroids was equal to, but certainly not better than eosinophil numbers.
Unfortunately we fbund that the prediction of a good clinical response in an individual
patient was poor. For instance, high sputurn eosinophils (>3%) correctly predicted a
significant improvement in PCse Mcli in only 65"/o of the patients.
A NOVEL MARKER OF AIRWAY INFLAMNIATION: EXHALED NITRIC
OXIDE
Since 1993. the small molecule exhaled nitric oxide (eNO) can be measured in exhaled air.
It was stated to be a non-invasive marker of airway inflamrnation in asthmatics 6. Early
repofts in international papers were enthusiastic about this nerv tool, stating that there was a
clear-cut ditference between asthmatics and healthy controls and that therefbre one could
easily discriminate between both groups. Moreover, the effects of ICS cor"rld be assessed by
eNO. After the first reports,.papers appeared reporling lesser discriminatory properlies and
pitfalls of measurements "". Two diffbrent ways of measurement were r.rsed; the tidal
breathing method'r:10, and the single breath rnethodll. ln Chapter,5 we compareci both
rnethods. We included asthma and COPD patients and compared them with healthy
controls diflerentiating between non-smokers and ex- or culrent smokers. We found that
mean eNO values were generaily significantly higher with the single breath method than
u'ith the tidal breathing method in nonsmoking and in smoking asthmatics and especially so
within the higher eNO ranges. This signifies that results are only comparable when the
same method is being used. Exhaled NO levels were not significantly different between ex-
smokers with COPD and healthv ex-snrokers.
In further research we identifled another pitfall of the eNO measurement. Exhaled NO is
measured by the so called chemiluminescence method. The chernical reaction of NO with
ozone was thought to be very specific. However, rve found a sharp increase in eNO ler.els
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alter cfeaning of tlre breathing system with an alcohol containing disinfectant. ln Chapter 6
we investigated the dif}-erence in eNO readings after a small spill of alcohol into the
breathing system versus a dry system free of alcohol contairring disinfectants. We fbund a
larger than 20olo increase in exhaled NO readings in the presence of alcohol. This is an
important factor in the accuracy of the measurement given the small differences found
between asthmatics and healthy subjects. We advise during the day not to clean the
breathing system rvith alcohol containing substances but only to change the mouthpiece to
prevent changes in NO readings of exhaled air.
Chemiluminescence is influenced by more substances than ethanol alone. The influence of
H2O and CO3 was studied in Chapter 7. A clear decrease of approximately 17% in NO
readings was shown when the sample was saturated with water compared to dry gas. We
therefore advise to insert a water absorber befure exhaled air enters the chemilunrinescence
analyser.
When these pitfblls of measurement are well controlled for, we confirmed that eNO levels
are very sensitive to corticosteroids and retum to levels in the normal range both with a
high and with a moderate dose of inhaled fluticasone (Chapter -l). Notwithstanding this, we
tbund that eNO levels do not predict the response to steroids very well (Chapter 4).
AIRWAY INFLAMMATION IS MORE CLOSELY ASSOCIATED WITH PC2O
ADENOSINE-5'-MONOPHOSPHATE (AMP) THAN WITH PC2O
METHACHOLINE.
Measurement of bronchial hyperresponsiveness is traditionally perfbnned with
methacholine or histamine. These substances act as direct stirnuli on airway smooth muscle
receptors. AMP acts as an indirect stimulus with possibly a small direct effect on airway
smooth muscle and a release of mediators by mast cells. In Chapter 3 we showed a larger
corticosteroid induced improvement in PC2p AMP compared to PC26 rnethacholine.
Therefbre our hypothesis in Chopter B was that PCuti AMP is more closely associated with
int1arnmation than PC26 rnethacholine. We analysed the cross-sectional association between
airway hyperresponsiveness as measured by AMP or methacholine and airway
inflammation. Inflammation was assessed by total cell counts and differentials as well as
mediators ( ECP and Il-8) in blood and sputum, as well as by exhaledNO (Chapter 8).
Cross sectional analyses showed that the variation in PC2e AMP was explained by
percentage ol sputum eosinophils and to a small extent by FEVl%predicted whereas
variation in PC2e Mch was rnainly explained by FEVl%predicted and to a smaller extent by
the percentage of blood monocytes. Moreover, the percentage of variance explained by the
eosinophilic inflammation was larger for PC2gAMP than fbr the PC2eMch.
In Chapter 9 we analysed the association between corticosteroid induced changes in
inflammation and changes irr PCzo AMP or methacholine. Mr.rltivariate analyses showed
that the improvement in PC:,r AMP responsiveness was solely related to the reduction in
airway inflammation (i.e. change in the number of sputum eosinophils, lymphocytes,
epithelial cells, and concentration of NO in exhaled air).
In contrast, improvement in PC:o methacholine was related to both the reduction in airway
inflammation and the increase in FEVI %predicted. The total explained variance of the
improvement in bronchial hyperresponsiveness was again greater for AMP than for
nrethacholine (36% versus 22o/o,respectively). From these 2 sfudies rve conclude that PC16
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AMP is a more promising tool for monitoring airu,ay inflammation and effects of anti-
inflammatory therapy than PCl2e methacholine. More prospective studies need, however, to
be performed.
RISK OF OVERUSE OF INHALED CORTICOSTEROIDS IN SELF-
MANAGEMENT PLANS
Asthma guidelines advocate the use of self-management plans. These guidelines adv'ise to
increase inhaled corticosteroids in a phase of unstable asthma but do not give clear
guidance on how and when to reduce the dose of inhaled corticosteroids. We were afraid
that this could lead to the use of relatively high doses of inhaled corticosteroids witlr
unwanted systenlic side effects. In Clwpter -10 an asthma self'-management plan lvas
investigated in a one year study that detemined whether this self management plan leads to
the use of a relatively high dose of ICS. The study starled with a relatively low dose of
inhaled tluticasone (200 pg/day) and used PEF and symptonrs as guidance fbr altering
treatment. In our study u,e also included exact guidance fbr reduction of inhaled
corticosteroids after a period of stable disease. A comparison was made with a group of
patients with a fixed, conventional dose of inhaled fluticasone (500 pg/day). The study
showed that there was no indication of 'overuse' of inhaled corticosteroids for rnost
patients withirr the self-nranagenlent group since a significantly lower rnean dose of 275
p,glday was found in this group than the mean dose of 500 prg/day within the fixed dose
group. No significant differences between both treatment strategies rvere fbund for both
clinical and inflarnmatory parameters.
Nevertheless, 3 patients were lound who used > 2000 pg/day within the self-managenrent
group. These patients were characterised by a low asthma quality of life score at the starl of
the study (4.2 compared to 5.4 on a scale of 0-7). Since no other measured parameters
ditfered with the remaining patients. these patients were labelled as "extreme perceivers" or
"hyperperceivers".
A search was also made which parameters could predict the end dose of inhaled 1-luticasone
within the self-management group. Only serum lgE and asthma qr"rality of life were found
to be independent predictors for the end dose of steroids. Moreover, these predictors
explained only l9oh of the variance in end dose of steroids, which is relatively poor and of
little value for choices in individual Datients.
TYPES AND CHARACTERISTICS OF ASTHMA EXACERBATIONS
Corticosteroids are the mainstay of the treatment and prevention of asthma exacerbations.
To study newly developed steroids and new intervention strategies. models of loss of
asthma control and models of asthma exacerbations are sought for, and controlled steroid
withdrawal has been used as such a model. Comparisons of steroid withdrawal and
spontaneous (real life) exacerbations are presented in Chapter 1/. We found striking
difl-erences between both types of exacerbations. Corticosteroid withdrarval exacerbations
were characterised by a higher o% of eosinophils in blood and sputum, IL-5 production by
stimulated PBMC's, and exhaled NO levels compared to spontaneous exacerbations. The
latter were characterised by a high o% of neutrophils in sputum compared to steroid
withdrawal exacerbations. This leads to the conclusion that steroid withdrawal
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exacerbations cannot be cornpared with spontaneous exacerbations during corticosteroid
maintenance therapy, but reflect loss of asthma control in general.
ROLE OF VIRUSES AND DER PI IN EXACERBATIONS
Triggers leading to an asthma exacerbation are still poorly understood. It is known that both
upper respiratory tract viruses and inhaled allergens like house dust mite, a common
allergen in Western Europe, can increase asthma symptoms and ainvay inflammation. We
detemrined the presence of viruses in nasal aspirates during both an exacerbation and
during a stable phase of the disease and fbund no significant difTerences between
exacerbation and stable periods. We describe a novel technique to approach allergen
exposure, i.e. measurement of allergen (Der pl) directly in sputum. Der pl levels were
detectable in 25ok of tlre sanrples, and did not shorv clear elevations during exacerbations.
The results do not support the imporlance of changes in Der p1 in relation to exacerbations
of  ast l rma in indi r  iduals
CONCLUSIONS
The main conclusions derived from the studies and review in this thesis are:
Asthma guidelines are not uniforrn in when and how to start with anti-
inflarnmatory therapy. Additionally, they offer n-rore explicit guidance in how to
increase the dose of inhaled corticosteroids than in how to decrease them.
Execution of self-managernent by patients is predominantly guided by changes in
symptoms and less by changes in PEF measured by a PEF meter and therefore we
prefer the use of symptoms above PEF, since the tbtmer can be more easily
monitored by the patient.
A high dose of inhaled fluticasone (2000 pg/day) given by Diskhaler is superior to
oral prednisolone (30 mg/day) given as start therapy for treatment of instable
asthma. -['his dose clearly reduces serum cortisol although less extensively so than
prednisolone. The clinical effects of a lower dose (500 pglday) are comparable to
olal prednisolone, but witlr less cortisol suppresslon.
Serum cortisol measurements by RIA method can be inf' luenced by systemic
prednisolone and should therefore be perfbrmed by HPLC method when
prednisolone can be present.
Prediction of benefits from corticosteroids in improving bronchial
hypenesponsiveness, FEVr, and asthma quality of life is predominantly
determined by their respective baseline values and to a smaller extent by blood and
sputum eosinophils. The individual prediction of response is, hou,ever, poor. ECP
levels do not have an additional value compared to blood or sputum eosinophils.
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Exhaled NO measurements are intluenced by nrany substances (H2O, ethanol,
smoking). Levels of exhaled NO are most clearly elevated in corticosteroid naive
patients. With proper measurements, exhaled nitric oxide is still not very usefirl as
a marker of ainvay inflammation while monitoring asthma, since eNO is not
elevated during spontaneous exacerbations under ICS treatment.
Adenosine-5'-lxonophosphate is more closely associated rvith airway inflammation
and more reflective of changes in inflammation with corticosteroid therapy than
methacholine and should be tested prospectively in clinical trials as a marker to
monitor eosinophilic inflammation in asthrna.
Astlrma self-management generally does not lead to the use of high doses of
inhaled corticosteroids. Patients using a self-management plan rvhile having a low
asthma quality of lit-e score are at higher risk for ending up with relatively high
doses of inhaled corticosteroids.
Steroid u,ithdrau'al induced exacerbations of asthma have a more eosinophil ic
pattem while spontaneous exacerbations during maintenance treatment with
inhaled corticosteroids have a more neutrophilic driven pattern. Exacerbations
induced by steroid withdrawal seem to reflect poor asthrna control in general,
rather than to resemble spontaneous exacerbations.
Viral particles measured by PCR in nasal secretions and Der pl antigens measured
by ELISA iIr induced sputum are detectable but are not elevated during ICS
withdrawal and spontaneous asthma exacerbations con.rpared to a stable phase of
asthma.
CENERAL DISCUSSION AND FUTURE PERSPECTI}'ES
Dosing of steroids
According to asthma guidelines it is agreed that all new prtients with symptoms of asthma
more than once a week shoLrld starl with corticosteroids ''. Even in rnild persistent asthma
this reduces exacerbations ''. From our o\\'n and from other studies we know that steroid
naive asthma patients do benefit from both oral and inhaled corticosteroids. Unexpectedly
we found a superior efficacy of inhaled f'luticasone propionate (1000 pg bid) versus oral
prednisolone (30 mg/day) as measured by improvement of airway hyperresponsiveness and
lung function while eosinophil levels u'ere reduced comparably. In contrast to suggestions
rnade in some asthma guidelines to start patients with nervly diagnosed asthma on a course
of oral steroids to gain quick and optimal control, we therefore suggest o start with inhaled
corticosteroids instead of oral prednisolone. Whether this is also advisable for asthma
exacerbations presenting at the ernergency departn.rent is less clear, but has been given
some creclibil i ty in recent trials Ia-r6. Full-scale trials of inhaled corticosteroids, or inhaled
corticosteroids with long acting B2-agonists, for the treatment of exacerbations are justified.
We submit that rare but serious side eft-ects of oral steroids, such as the induction of
diabetes, would be prevented when oral prednisolone could be averled. Furtherrnore, tl-re
institution of oral prednisolone is frequently delayed for sorne time early in the course of a
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